glp 1 drugs and lupus Glucagon-like peptide its receptor agonists for the treatment of rheumatic diseases GLP-1 Drugs Show Benefits in

Studies show that adding lifestyle changes to GLP-1 treatment can reduce cardiovascular risk by up to 43 percent

Verdile G, Keane KN, Cruzat VF, et al

These processes interact with one another in a pathological feed-forward cycle, ultimately yielding functional and structural kidney abnormalities characteristic of diabetic kidney disease (DKD) (Fig

Compromised patient safety Doses affected by thermal degradation may deliver subtherapeutic results, delaying treatment progress or worsening health outcomes in vulnerable patient populations

However, the medication's gastrointestinal effectsparticularly nausea, vomiting, and diarrheacan lead to dehydration and prerenal acute kidney injury if fluid intake is inadequate